Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05954065 · ClinicalTrials.gov registry record
An Evaluation of the Effect of the Erchonia Laser for Non-invasive Reduction of Submental Fat
A clinical trial, sponsored by Erchonia Corporation.
- Completed
- Registry status
- 31
- Enrollment target
NCT05954065: Completed study, sponsored by Erchonia Corporation.
NCT05954065 is a clinical trial that has completed, run by Erchonia Corporation. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05954065 has completed, sponsored by Erchonia Corporation.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to determine the effectiveness of the Erchonia® CFL (manufactured by Erchonia Corporation (the Company), in providing noninvasive fat reduction in the submental area.
Primary Outcome
Reviewers will be blinded to post-treatment (12 weeks post) vs. baseline untreated area. The order in which images will be presented will be randomized. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. Success is defined as at least 2 of the 3 blinded evaluators correctly identifying a subject's pre-treatment and post-treatment (study endpoint) photographs for 80% or more of subjects.
Interventions
- DEVICE Erchonia CFL Laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2024-09-30 |
What the finished NCT05954065 record still lists
NCT05954065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Erchonia CFL Laser is the first listed.
NCT05954065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05954065 about?
NCT05954065 is a clinical study titled "An Evaluation of the Effect of the Erchonia Laser for Non-invasive Reduction of Submental Fat". The purpose of this clinical study is to determine the effectiveness of the Erchonia® CFL (manufactured by Erchonia Corporation (the Company), in providing noninvasive fat reduction in the submental area.
What is the current status of trial NCT05954065?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2023-07-12. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT05954065?
The interventions under investigation include: Erchonia CFL Laser (DEVICE).
Who is sponsoring clinical trial NCT05954065?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI